An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability

Multiple mutation combinations in the IgG Fc have been characterized to tailor immune effector function or IgG serum persistence to fit desired biological outcomes for monoclonal antibody therapeutics. An unintended consequence of introducing mutations in the Fc (particularly the CH2 domain) can be...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of pharmaceutical sciences 2017-04, Vol.106 (4), p.1008-1017
Hauptverfasser: Borrok, M. Jack, Mody, Neil, Lu, Xiaojun, Kuhn, Megan L., Wu, Herren, Dall'Acqua, William F., Tsui, Ping
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1017
container_issue 4
container_start_page 1008
container_title Journal of pharmaceutical sciences
container_volume 106
creator Borrok, M. Jack
Mody, Neil
Lu, Xiaojun
Kuhn, Megan L.
Wu, Herren
Dall'Acqua, William F.
Tsui, Ping
description Multiple mutation combinations in the IgG Fc have been characterized to tailor immune effector function or IgG serum persistence to fit desired biological outcomes for monoclonal antibody therapeutics. An unintended consequence of introducing mutations in the Fc (particularly the CH2 domain) can be a reduction in biophysical stability which can correlate with increased aggregation propensity, poor manufacturability, and lower solubility. Herein, we characterize the changes in IgG conformational and colloidal stability when 2 sets of CH2 mutations “TM” (L234F/L235E/P331S) and “YTE” (M252Y/S254T/T256E) are combined to generate an antibody format lacking immune receptor binding and exhibiting extended half-life. In addition to significantly lowered thermostability, we observe greater conformational flexibility for TM-YTE in CH2, increased self-association, and poorer solubility and aggregation profiles. To improve these properties, we dissected the contributions of individual mutations within TM-YTE on thermostability and substituted destabilizing mutations with new mutations that raise thermostability. One novel combination, FQQ-YTE (L234F/L235Q/K322Q/M252Y/S254T/T256E), had significantly improved conformational and colloidal stability, and was found to retain the same biological activities as TM-YTE (extended half-life and lack of antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activity). Our engineering approach offers a way to improve the developability of antibodies containing Fc mutations while retaining tailored biological activity.
doi_str_mv 10.1016/j.xphs.2016.12.023
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1856592798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0022354916419490</els_id><sourcerecordid>1856592798</sourcerecordid><originalsourceid>FETCH-LOGICAL-c400t-d90aa6c99cb9eb2fa7f4458a43c699b50b123e6ac118ede7b82973adf45fff743</originalsourceid><addsrcrecordid>eNp9kLtOxDAQRS0EguXxAxQoJU3C2ImTWKJBwMJKK1EAgs5ynDF4lcdiZxF0fAj8HF-ClwVKqnno3quZQ8g-hYQCzY9mycv80Scs9AllCbB0jYwoZxDnQIt1MgJgLE55JrbItvczAMiB802yxUrgBc_YiNyfdNHn2_tYx9e2wU5j_fn2EU0eLmg07l2rhujODo_R-cuAXY11dKkaE0-twegMvX3owsr0Lpq0c9c_h-F6UJVt7PC6SzaMajzu_dQdcjs-vzm9jKdXF5PTk2msM4AhrgUolWshdCWwYkYVJst4qbJU50JUHCrKUsyVprTEGouqZKJIVW0ybowpsnSHHK5ywwFPC_SDbK3X2DSqw37hJS15zgUrRBmkbCXVrvfeoZFzZ1vlXiUFuSQqZ3JJVC6JSspkIBpMBz_5i6rF-s_yizAIjlcCDF8-W3TSa_tN0jrUg6x7-1_-FzANiJ0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1856592798</pqid></control><display><type>article</type><title>An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Borrok, M. Jack ; Mody, Neil ; Lu, Xiaojun ; Kuhn, Megan L. ; Wu, Herren ; Dall'Acqua, William F. ; Tsui, Ping</creator><creatorcontrib>Borrok, M. Jack ; Mody, Neil ; Lu, Xiaojun ; Kuhn, Megan L. ; Wu, Herren ; Dall'Acqua, William F. ; Tsui, Ping</creatorcontrib><description>Multiple mutation combinations in the IgG Fc have been characterized to tailor immune effector function or IgG serum persistence to fit desired biological outcomes for monoclonal antibody therapeutics. An unintended consequence of introducing mutations in the Fc (particularly the CH2 domain) can be a reduction in biophysical stability which can correlate with increased aggregation propensity, poor manufacturability, and lower solubility. Herein, we characterize the changes in IgG conformational and colloidal stability when 2 sets of CH2 mutations “TM” (L234F/L235E/P331S) and “YTE” (M252Y/S254T/T256E) are combined to generate an antibody format lacking immune receptor binding and exhibiting extended half-life. In addition to significantly lowered thermostability, we observe greater conformational flexibility for TM-YTE in CH2, increased self-association, and poorer solubility and aggregation profiles. To improve these properties, we dissected the contributions of individual mutations within TM-YTE on thermostability and substituted destabilizing mutations with new mutations that raise thermostability. One novel combination, FQQ-YTE (L234F/L235Q/K322Q/M252Y/S254T/T256E), had significantly improved conformational and colloidal stability, and was found to retain the same biological activities as TM-YTE (extended half-life and lack of antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activity). Our engineering approach offers a way to improve the developability of antibodies containing Fc mutations while retaining tailored biological activity.</description><identifier>ISSN: 0022-3549</identifier><identifier>EISSN: 1520-6017</identifier><identifier>DOI: 10.1016/j.xphs.2016.12.023</identifier><identifier>PMID: 28057542</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Animals ; benign blocker ; biotechnology ; calorimetry (DSC) ; CH2 ; developability ; Fc-silenced ; Gene Silencing ; Half-Life ; HEK293 Cells ; Humans ; IgG antibody ; Immunoglobulin Fc Fragments - chemistry ; Immunoglobulin Fc Fragments - genetics ; Immunoglobulin G - chemistry ; Immunoglobulin G - genetics ; immunology ; light scattering (dynamic) ; Mice, 129 Strain ; Mice, Inbred C57BL ; Mice, Transgenic ; Mutation - genetics ; pharmacokinetics ; protein aggregation ; Protein Stability ; Protein Structure, Secondary ; Protein Structure, Tertiary ; Receptors, IgG - chemistry ; Receptors, IgG - genetics ; thermal analysis</subject><ispartof>Journal of pharmaceutical sciences, 2017-04, Vol.106 (4), p.1008-1017</ispartof><rights>2017 American Pharmacists Association</rights><rights>Copyright © 2017 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c400t-d90aa6c99cb9eb2fa7f4458a43c699b50b123e6ac118ede7b82973adf45fff743</citedby><cites>FETCH-LOGICAL-c400t-d90aa6c99cb9eb2fa7f4458a43c699b50b123e6ac118ede7b82973adf45fff743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28057542$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Borrok, M. Jack</creatorcontrib><creatorcontrib>Mody, Neil</creatorcontrib><creatorcontrib>Lu, Xiaojun</creatorcontrib><creatorcontrib>Kuhn, Megan L.</creatorcontrib><creatorcontrib>Wu, Herren</creatorcontrib><creatorcontrib>Dall'Acqua, William F.</creatorcontrib><creatorcontrib>Tsui, Ping</creatorcontrib><title>An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability</title><title>Journal of pharmaceutical sciences</title><addtitle>J Pharm Sci</addtitle><description>Multiple mutation combinations in the IgG Fc have been characterized to tailor immune effector function or IgG serum persistence to fit desired biological outcomes for monoclonal antibody therapeutics. An unintended consequence of introducing mutations in the Fc (particularly the CH2 domain) can be a reduction in biophysical stability which can correlate with increased aggregation propensity, poor manufacturability, and lower solubility. Herein, we characterize the changes in IgG conformational and colloidal stability when 2 sets of CH2 mutations “TM” (L234F/L235E/P331S) and “YTE” (M252Y/S254T/T256E) are combined to generate an antibody format lacking immune receptor binding and exhibiting extended half-life. In addition to significantly lowered thermostability, we observe greater conformational flexibility for TM-YTE in CH2, increased self-association, and poorer solubility and aggregation profiles. To improve these properties, we dissected the contributions of individual mutations within TM-YTE on thermostability and substituted destabilizing mutations with new mutations that raise thermostability. One novel combination, FQQ-YTE (L234F/L235Q/K322Q/M252Y/S254T/T256E), had significantly improved conformational and colloidal stability, and was found to retain the same biological activities as TM-YTE (extended half-life and lack of antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activity). Our engineering approach offers a way to improve the developability of antibodies containing Fc mutations while retaining tailored biological activity.</description><subject>Animals</subject><subject>benign blocker</subject><subject>biotechnology</subject><subject>calorimetry (DSC)</subject><subject>CH2</subject><subject>developability</subject><subject>Fc-silenced</subject><subject>Gene Silencing</subject><subject>Half-Life</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>IgG antibody</subject><subject>Immunoglobulin Fc Fragments - chemistry</subject><subject>Immunoglobulin Fc Fragments - genetics</subject><subject>Immunoglobulin G - chemistry</subject><subject>Immunoglobulin G - genetics</subject><subject>immunology</subject><subject>light scattering (dynamic)</subject><subject>Mice, 129 Strain</subject><subject>Mice, Inbred C57BL</subject><subject>Mice, Transgenic</subject><subject>Mutation - genetics</subject><subject>pharmacokinetics</subject><subject>protein aggregation</subject><subject>Protein Stability</subject><subject>Protein Structure, Secondary</subject><subject>Protein Structure, Tertiary</subject><subject>Receptors, IgG - chemistry</subject><subject>Receptors, IgG - genetics</subject><subject>thermal analysis</subject><issn>0022-3549</issn><issn>1520-6017</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtOxDAQRS0EguXxAxQoJU3C2ImTWKJBwMJKK1EAgs5ynDF4lcdiZxF0fAj8HF-ClwVKqnno3quZQ8g-hYQCzY9mycv80Scs9AllCbB0jYwoZxDnQIt1MgJgLE55JrbItvczAMiB802yxUrgBc_YiNyfdNHn2_tYx9e2wU5j_fn2EU0eLmg07l2rhujODo_R-cuAXY11dKkaE0-twegMvX3owsr0Lpq0c9c_h-F6UJVt7PC6SzaMajzu_dQdcjs-vzm9jKdXF5PTk2msM4AhrgUolWshdCWwYkYVJst4qbJU50JUHCrKUsyVprTEGouqZKJIVW0ybowpsnSHHK5ywwFPC_SDbK3X2DSqw37hJS15zgUrRBmkbCXVrvfeoZFzZ1vlXiUFuSQqZ3JJVC6JSspkIBpMBz_5i6rF-s_yizAIjlcCDF8-W3TSa_tN0jrUg6x7-1_-FzANiJ0</recordid><startdate>201704</startdate><enddate>201704</enddate><creator>Borrok, M. Jack</creator><creator>Mody, Neil</creator><creator>Lu, Xiaojun</creator><creator>Kuhn, Megan L.</creator><creator>Wu, Herren</creator><creator>Dall'Acqua, William F.</creator><creator>Tsui, Ping</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201704</creationdate><title>An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability</title><author>Borrok, M. Jack ; Mody, Neil ; Lu, Xiaojun ; Kuhn, Megan L. ; Wu, Herren ; Dall'Acqua, William F. ; Tsui, Ping</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c400t-d90aa6c99cb9eb2fa7f4458a43c699b50b123e6ac118ede7b82973adf45fff743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Animals</topic><topic>benign blocker</topic><topic>biotechnology</topic><topic>calorimetry (DSC)</topic><topic>CH2</topic><topic>developability</topic><topic>Fc-silenced</topic><topic>Gene Silencing</topic><topic>Half-Life</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>IgG antibody</topic><topic>Immunoglobulin Fc Fragments - chemistry</topic><topic>Immunoglobulin Fc Fragments - genetics</topic><topic>Immunoglobulin G - chemistry</topic><topic>Immunoglobulin G - genetics</topic><topic>immunology</topic><topic>light scattering (dynamic)</topic><topic>Mice, 129 Strain</topic><topic>Mice, Inbred C57BL</topic><topic>Mice, Transgenic</topic><topic>Mutation - genetics</topic><topic>pharmacokinetics</topic><topic>protein aggregation</topic><topic>Protein Stability</topic><topic>Protein Structure, Secondary</topic><topic>Protein Structure, Tertiary</topic><topic>Receptors, IgG - chemistry</topic><topic>Receptors, IgG - genetics</topic><topic>thermal analysis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Borrok, M. Jack</creatorcontrib><creatorcontrib>Mody, Neil</creatorcontrib><creatorcontrib>Lu, Xiaojun</creatorcontrib><creatorcontrib>Kuhn, Megan L.</creatorcontrib><creatorcontrib>Wu, Herren</creatorcontrib><creatorcontrib>Dall'Acqua, William F.</creatorcontrib><creatorcontrib>Tsui, Ping</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of pharmaceutical sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Borrok, M. Jack</au><au>Mody, Neil</au><au>Lu, Xiaojun</au><au>Kuhn, Megan L.</au><au>Wu, Herren</au><au>Dall'Acqua, William F.</au><au>Tsui, Ping</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability</atitle><jtitle>Journal of pharmaceutical sciences</jtitle><addtitle>J Pharm Sci</addtitle><date>2017-04</date><risdate>2017</risdate><volume>106</volume><issue>4</issue><spage>1008</spage><epage>1017</epage><pages>1008-1017</pages><issn>0022-3549</issn><eissn>1520-6017</eissn><abstract>Multiple mutation combinations in the IgG Fc have been characterized to tailor immune effector function or IgG serum persistence to fit desired biological outcomes for monoclonal antibody therapeutics. An unintended consequence of introducing mutations in the Fc (particularly the CH2 domain) can be a reduction in biophysical stability which can correlate with increased aggregation propensity, poor manufacturability, and lower solubility. Herein, we characterize the changes in IgG conformational and colloidal stability when 2 sets of CH2 mutations “TM” (L234F/L235E/P331S) and “YTE” (M252Y/S254T/T256E) are combined to generate an antibody format lacking immune receptor binding and exhibiting extended half-life. In addition to significantly lowered thermostability, we observe greater conformational flexibility for TM-YTE in CH2, increased self-association, and poorer solubility and aggregation profiles. To improve these properties, we dissected the contributions of individual mutations within TM-YTE on thermostability and substituted destabilizing mutations with new mutations that raise thermostability. One novel combination, FQQ-YTE (L234F/L235Q/K322Q/M252Y/S254T/T256E), had significantly improved conformational and colloidal stability, and was found to retain the same biological activities as TM-YTE (extended half-life and lack of antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity activity). Our engineering approach offers a way to improve the developability of antibodies containing Fc mutations while retaining tailored biological activity.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>28057542</pmid><doi>10.1016/j.xphs.2016.12.023</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-3549
ispartof Journal of pharmaceutical sciences, 2017-04, Vol.106 (4), p.1008-1017
issn 0022-3549
1520-6017
language eng
recordid cdi_proquest_miscellaneous_1856592798
source MEDLINE; Alma/SFX Local Collection
subjects Animals
benign blocker
biotechnology
calorimetry (DSC)
CH2
developability
Fc-silenced
Gene Silencing
Half-Life
HEK293 Cells
Humans
IgG antibody
Immunoglobulin Fc Fragments - chemistry
Immunoglobulin Fc Fragments - genetics
Immunoglobulin G - chemistry
Immunoglobulin G - genetics
immunology
light scattering (dynamic)
Mice, 129 Strain
Mice, Inbred C57BL
Mice, Transgenic
Mutation - genetics
pharmacokinetics
protein aggregation
Protein Stability
Protein Structure, Secondary
Protein Structure, Tertiary
Receptors, IgG - chemistry
Receptors, IgG - genetics
thermal analysis
title An “Fc-Silenced” IgG1 Format With Extended Half-Life Designed for Improved Stability
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T00%3A25%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20%E2%80%9CFc-Silenced%E2%80%9D%20IgG1%20Format%20With%20Extended%20Half-Life%20Designed%20for%20Improved%20Stability&rft.jtitle=Journal%20of%20pharmaceutical%20sciences&rft.au=Borrok,%20M.%20Jack&rft.date=2017-04&rft.volume=106&rft.issue=4&rft.spage=1008&rft.epage=1017&rft.pages=1008-1017&rft.issn=0022-3549&rft.eissn=1520-6017&rft_id=info:doi/10.1016/j.xphs.2016.12.023&rft_dat=%3Cproquest_cross%3E1856592798%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1856592798&rft_id=info:pmid/28057542&rft_els_id=S0022354916419490&rfr_iscdi=true